The Zhitong Finance App learned that on Wednesday, Merck (MRK.US) rose nearly 10% to $148.44. Moderna (MRNA.US) surged more than 113% to $134.51. According to the news, Moderna and MSD announced today that the personalized mRNA cancer vaccine jointly developed by the two companies achieved positive results in a large-scale phase III clinical trial, marking that mRNA technology ushered in the first successful phase III trial in the field of cancer treatment. It is also a major breakthrough in personalized immunotherapy in the history of cancer treatment.

The Zhitong Finance App learned that on Wednesday, Merck (MRK.US) rose nearly 10% to $148.44. Moderna (MRNA.US) surged more than 113% to $134.51. According to the news, Moderna and MSD announced today that the personalized mRNA cancer vaccine jointly developed by the two companies achieved positive results in a large-scale phase III clinical trial, marking that mRNA technology ushered in the first successful phase III trial in the field of cancer treatment. It is also a major breakthrough in personalized immunotherapy in the history of cancer treatment.